hydralazine has been researched along with sildenafil citrate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becher, PM; Fröhlich, M; Hoffmann, S; Lindner, D; Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D; Xia, Y | 1 |
| Attinà, TM; Drummond, ID; Malatino, LS; Maxwell, SR; Webb, DJ | 1 |
1 trial(s) available for hydralazine and sildenafil citrate
| Article | Year |
|---|---|
Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men.
Topics: Adult; Blood Pressure; Exercise; Exercise Tolerance; Humans; Hydralazine; Hypertension; Male; Middle Aged; Oxygen Consumption; Phosphodiesterase 5 Inhibitors; Piperazines; Pulse Wave Analysis; Purines; Sildenafil Citrate; Sulfones; Vascular Stiffness | 2013 |
1 other study(ies) available for hydralazine and sildenafil citrate
| Article | Year |
|---|---|
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic Nucleotide Phosphodiesterases, Type 5; Cytokines; Extracellular Matrix; Heart Failure; Heart Function Tests; Hydralazine; Male; Mice; Mice, Inbred C57BL; Myocarditis; Myocardium; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Sildenafil Citrate; Sulfones; Vasoconstrictor Agents; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2012 |